Robert N. Willette

10.6k total citations · 1 hit paper
132 papers, 7.5k citations indexed

About

Robert N. Willette is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Robert N. Willette has authored 132 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 39 papers in Cardiology and Cardiovascular Medicine and 35 papers in Physiology. Recurrent topics in Robert N. Willette's work include Neuroscience of respiration and sleep (22 papers), Nitric Oxide and Endothelin Effects (20 papers) and Neuropeptides and Animal Physiology (14 papers). Robert N. Willette is often cited by papers focused on Neuroscience of respiration and sleep (22 papers), Nitric Oxide and Endothelin Effects (20 papers) and Neuropeptides and Animal Physiology (14 papers). Robert N. Willette collaborates with scholars based in United States, United Kingdom and Australia. Robert N. Willette's co-authors include Hreday N. Sapru, Abbott J. Krieger, Frank C. Barone, G Feuerstein, Paul G. Lysko, Eliot H. Ohlstein, Charles F. Sauermelch, Susan Punnen, Ray F. White and C. L. Webb and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and PLoS ONE.

In The Last Decade

Robert N. Willette

131 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Necrosis Factor-α

1997 748 citations Frank C. Barone, Robert N. Willette et al. profile →

Peers

Countries citing papers authored by Robert N. Willette

Since Specialization

Citations

This map shows the geographic impact of Robert N. Willette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert N. Willette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert N. Willette more than expected).

Fields of papers citing papers by Robert N. Willette

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert N. Willette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert N. Willette. The network helps show where Robert N. Willette may publish in the future.

Co-authorship network of co-authors of Robert N. Willette

This figure shows the co-authorship network connecting the top 25 collaborators of Robert N. Willette. A scholar is included among the top collaborators of Robert N. Willette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert N. Willette. Robert N. Willette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CXA-10, a Nitrated Fatty Acid, Is Renoprotective in Deoxycorticosterone Acetate-Salt Nephropathy 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Cynthia Arbeeny, Hong Ling, (unknown), (unknown), Stefan Wawersik, Steven Ledbetter, (unknown), Francisco J. Schöpfer, Robert N. Willette, Diane K. Jorkasky	23
2	Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome 2017 ·PLoS ONE ·Feby Savira, Longxing Cao, Ian Wang, Wendi Yang, (unknown), Hua Yue, Beat M. Jucker, Robert N. Willette, Li Huang, Henry Krum, Zhiliang Li, Qiang Fu, Bing H. Wang	29
3	The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits 2017 ·PLoS ONE ·Jin Zhou, Jie Li, Daniel M. Rosenbaum, Jian Zhuang, Carrie Poon, Pu Qin, (unknown), John J. Lepore, Robert N. Willette, Erding Hu, Frank C. Barone	30
4	Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy 2014 ·Proceedings of the National Academy of Sciences ·Kinya Seo, Peter P. Rainer, Virginia S. Hahn, Dong-Ik Lee, Su‐Hyun Jo, Asger Andersen, Ting Liu, Xiaoping Xu, Robert N. Willette, John J. Lepore, Joseph P. Marino, Lutz Birnbaumer, Christine G. Schnackenberg, David A. Kass	160
5	Soluble Epoxide Hydrolase Inhibition Does Not Prevent Cardiac Remodeling and Dysfunction After Aortic Constriction in Rats and Mice 2012 ·Journal of Cardiovascular Pharmacology ·Lisa Morgan, Alan R. Olzinski, John J. Upson, Shufang Zhao, Tao Wang, Stephen Eisennagel, Bao Hoang, James Tunstead, Joseph P. Marino, Robert N. Willette, Beat M. Jucker, David J. Behm	22
6	Abstract 12344: Apoptosis Signal-Regulating Kinase 1 Inhibition Attenuates Cardiac Myocyte Hypertrophy and Fibroblast Collagen Synthesis Stimulated by Angiotensin II- and TGFβ: Therapeutic Potential of ASK1 Inhibitors in Myocardial Remodelling 2011 ·Circulation ·Bing H. Wang, (unknown), (unknown), Andrew R. Kompa, Beat M. Jucker, Robert N. Willette, Henry Krum	2
7	Serial MRI characterization of the functional and morphological changes in mouse lung in response to cardiac remodeling following myocardial infarction 2011 ·Magnetic Resonance in Medicine ·Hasan Alsaid, Weike Bao, (unknown), (unknown), David J. Figueroa, Stephen C. Lenhard, Charles J. Kotzer, Mark Burgert, Robert N. Willette, Victor A. Ferrari, Beat M. Jucker	5
8	Inhibition of p38 Mitogen-Activated Protein Kinase Attenuates Vascular and Systemic Inflammation in Patients with Atherosclerosis as Assessed by 18-F Fluorodeoxyglucose PET-CT 2010 ·Circulation ·Maysoon Elkhawad, (unknown), Lea Sarov‐Blat, Michael Marber, Robin P. Choudhury, Lawrence Davies, David Collier, Gengqian Cai, Robert N. Willette, Fergus Gleeson, John J. Lepore, Bill Davis, Ian B. Wilkinson, Dennis L. Sprecher, Joseph Cheriyan	3
9	Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat 2010 ·Journal of Cardiovascular Pharmacology ·Weike Bao, Pu Qin, Saul Needle, Connie L. Erickson‐Miller, Kevin J. Duffy, Jennifer L. Ariazi, Shufang Zhao, Alan R. Olzinski, David J. Behm, G. C. Teg Pipes, Beat M. Jucker, Erding Hu, John J. Lepore, Robert N. Willette	88
10	Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Robert N. Willette, Marianne Eybye, Alan R. Olzinski, David J. Behm, Nambi Aiyar, Kristeen Maniscalco, Ross Bentley, Robert W. Coatney, Shufang Zhao, Timothy D. Westfall, Chris P. Doe	37
11	In Vivo Activation of Peroxisome Proliferator-Activated Receptor-δ Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats 2008 ·Journal of Pharmacology and Experimental Therapeutics ·Tianli Yue, Sandhya S. Nerurkar, Weike Bao, Beat M. Jucker, Lea Sarov‐Blat, Klaudia Steplewski, Eliot H. Ohlstein, Robert N. Willette	59
12	Carvedilol Prevents and Reverses Hypertrophy-Induced Cardiac Dysfunction 2007 ·Pharmacology ·Frank C. Barone, Robert N. Willette, Allen H. Nelson, Eliot H. Ohlstein, David P. Brooks, Robert W. Coatney	13
13	Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production 2007 ·Journal of Cardiovascular Pharmacology ·Weike Bao, David J. Behm, Sandhya S. Nerurkar, Zhaohui Ao, Ross Bentley, Rosanna C. Mirabile, Douglas G. Johns, (unknown), Christopher Doe, Robert W. Coatney, Jason F. Ohlstein, Stephen A. Douglas, Robert N. Willette, Tianli Yue	89
14	The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems 2006 ·British Journal of Pharmacology ·David J. Behm, Gerald P. Stankus, Christopher Doe, Robert N. Willette, Henry M. Sarau, James J. Foley, Dulcie B. Schmidt, Parvathi Nuthulaganti, James A. Fornwald, Robert S. Ames, David G. Lambert, Girolamo Calò, Valeria Camarda, Nambi Aiyar, Stephen A. Douglas	32
15	p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Haisong Ju, David J. Behm, (unknown), Marianne Eybye, (unknown), Alan R. Olzinski, Stephen A. Douglas, Robert N. Willette	54
16	Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1? mRNA in ischemic brain tolerance 2000 ·Journal of Neuroscience Research ·Xinkang Wang, Xiang Li, R. William Currie, Robert N. Willette, Frank C. Barone, Giora Feuerstein	68
17	BMP-2 Gene Expression and Effects on Human Vascular Smooth Muscle Cells 1999 ·Journal of Vascular Research ·Robert N. Willette, (unknown), Paul G. Lysko, Karen M. Anderson, (unknown), Tianli Yue	110
18	Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat 1990 ·European Journal of Pharmacology ·Robert N. Willette, Charles F. Sauermelch, Robert Ruffolo	5
19	Activation of cholinergic mechanisms in the medulla oblongata reverse intravenous opioid-induced respiratory depression. 1987 ·Journal of Pharmacology and Experimental Therapeutics ·Robert N. Willette, (unknown), Hreday N. Sapru	37
20	Analgetic Drugs—A Re-evaluation 1970 ·American Journal of Pharmaceutical Education ·Robert N. Willette	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact